The biological significance of tumor grade, age, enhancement and extent of resection in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review.

التفاصيل البيبلوغرافية
العنوان:	The biological significance of tumor grade, age, enhancement and extent of resection in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review.
المؤلفون:	van den Bent MJ; Brain Tumor Center at ErasmusMC Cancer Institute, Rotterdam, the Netherlands., French PJ; Brain Tumor Center at ErasmusMC Cancer Institute, Rotterdam, the Netherlands., Brat D; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL., Tonn JC; Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany and German Cancer Consortium (DKTK), Partner Site Munich, Germany., Touat M; Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, Paris Brain Institute, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA., Ellingson BM; UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine at UCLA., Young RJ; Neuroradiology Service, Department of Radiology, Memorial Sloan Kettering Cancer, New York, NY USA., Pallud J; Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Site Sainte Anne, F-75014 Paris, France.; Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-Brain, F-75014 Paris, France., von Deimling A; Dept. of Neuropathology, University Hospital Medicine and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Sahm F; Dept. of Neuropathology, University Hospital Medicine and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Figarella Branger D; DFB Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France., Huang RY; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA., Weller M; Department of Neurology & Brain Tumor Center, University Hospital Zurich & University of Zurich, Zurich, Switzerland., Mellinghoff IK; Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY., Cloughsey TF; TC David Geffen School of Medicine at UCLA, Department of Neurology., Huse JT; Department of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Aldape K; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA., Reifenberger G; Institute of Neuropathology, Medical Faculty, Heinrich Heine University and University Hospital Düsseldorf, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany., Youssef G; Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Karschnia P; Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Germany., Noushmehr H; Department of Neurosurgery, Henry Ford Hospital+Michigan State University, Detroit, Michigan, USA., Peters KB; Department of Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA., Ducray F; Hospices Civils de Lyon, Service de neuro-oncologie, LabEx Dev2CAN, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon, Lyon, France., Preusser M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Wen PY; Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
المصدر:	Neuro-oncology [Neuro Oncol] 2024 Jun 24. Date of Electronic Publication: 2024 Jun 24.
Publication Model:	Ahead of Print
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE
أسماء مطبوعة:	Publication: 2010- : Oxford : Oxford University Press Original Publication: 1999-<2002> : Charlottesville, VA : Carden Jennings Pub.,
مستخلص:	The 2016 and 2021 World Health Organization (WHO) 2021 Classification of Central Nervous System (CNS) tumors have resulted in a major improvement of the classification of IDH-mutant gliomas. With more effective treatments many patients experience prolonged survival . However, treatment guidelines are often still based on information from historical series comprising both patients with IDHwt and IDH mutant tumors. They provide recommendations for radiotherapy and chemotherapy for so-called high-risk patients, usually based on residual tumor after surgery and age over 40. More up-to-date studies give a better insight into clinical, radiological and molecular factors associated with outcome of patients with IDH-mutant glioma. These insights should be used today for risk stratification and for treatment decisions. In many patients with an IDH-mutant grade 2 and grade 3 glioma, if carefully monitored postponing radiotherapy and chemotherapy is safe, and will not jeopardize overall outcome of patients. With the INDIGO trial showing patient benefit from the IDH inhibitor vorasidenib, there is a sizable population in which it seems reasonable to try this class of agents before recommending radio-chemotherapy with its delayed adverse event profile affecting quality of survival. Ongoing trials should help to further identify the patients that are benefiting from this treatment. (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)
فهرسة مساهمة:	Keywords: Astrocytoma IDH-mutant; WHO brain tumor classification; oligodendroglioma IDH-mutant and 1p/19q codeleted; prognosis; vorasidenib
تواريخ الأحداث:	Date Created: 20240624 Latest Revision: 20240624
رمز التحديث:	20240624
DOI:	10.1093/neuonc/noae107
PMID:	38912846
قاعدة البيانات:	MEDLINE

Full Text Finder

الوصف
تدمد:	1523-5866
DOI:	10.1093/neuonc/noae107